Sarcopenia Prevalence and Influence on the Development of Toxicity and Length of Stay in Patients with Relapsed and Refractory Myeloma Treated with Commercial Anti-BCMA CART Cells

Parker, Nathan H.; Modi, Karnav; Villanueva, Ricardo; Skelson, Lawrence; Scotto, Ashley; Booth-Jones, Margaret; Avila, Gabriel De; Jain, Michael D.; Mishra, Asmita; Faramand, Rawan; Akhtar, Othman Salim; Brayer, Jason; Puglianini, Omar Castaneda; Grajales-Cruz, Ariel; Baz, Rachid; Blue, Brandon; Shain, Kenneth H.; Alsina, Melissa; Liu, Hien; Nishihori, Taiga; Locke, Frederick L.; Hansen, Doris K.; Freeman, Ciara L.

doi:10.1182/blood-2022-168071

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, one recent study demonstrated that sarcopenia was associated with an increased risk of ICANS and longer length of hospital stay. 83 Consistently gathering additional data (including geriatric assessment) 84,85 about the baseline health of individuals enrolled in clinical trials of CAR T-cell and BsAbs will improve clinicians' insight into whether their patients are similar to those treated on trial and identify those who may be at increased risk for toxicity, allowing more informed shared decision making.…”

Section: Access To Care and Equity In Real-world Settingsmentioning

confidence: 99%

Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma: Moving Into the Future

Holstein

Grant

Wildes

2023

JCO

View full text Add to dashboard Cite

Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory multiple myeloma (MM) have been poor because of a dearth of effective treatment options. However, the advent of chimeric antigen receptor (CAR) T-cell and T-cell redirecting bispecific antibody (BsAb) therapies has led to unprecedented response rates and durations of response in heavily relapsed/refractory (R/R) populations. Currently, two B-cell maturation antigen (BCMA)–directed CAR T-cell therapies (idecabtagene vicleucel and ciltacabtagene autoleucel) as well as one BCMA/CD3 BsAb (teclistamab) have been approved for late-line (greater than four previous lines) R/R MM in the United States. The purpose of this review is to analyze the recent data for these approved therapies as well as provide an overview of other related CAR T-cell and BsAb therapies under development, including non–BCMA-targeting agents. We review efficacy and safety considerations, with particular focus on cytokine release syndrome, neurotoxicity, and infection risk. The relative merits and limitations of each class of therapy are discussed, as well as the areas of unmet need with respect to optimal sequencing and supportive care measures. We examine the factors that challenge equitable access to these novel therapies across minoritized racial, ethnic, and socioeconomic populations. Although it is evident that CAR T-cell and BsAb therapies will transform treatment paradigms in MM for years to come, significant work remains to identify the optimal utilization of these novel therapies and ensure equitable access.

show abstract

Section: Access To Care and Equity In Real-world Settingsmentioning

confidence: 99%